BTIG maintains $121 price target on Syre Therapeutics
BTIG maintained a $121.00/share price target for Syre Therapeutics, according to Benzinga ratings actions.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.